Product Comparison


 
Glaxo Specialty (Medical Benefit) 49401010101
Roche 00004029809
Novartis 00078024615

No Image
Glaxo Specialty (Medical Benefit) 49401010201
McKesson # 1184514 795875 897151 1184270 1184516
Description Benlysta® Belimumab 120 mg Injection Single-Use Vial 5 mL CellCept® Mycophenolate Mofetil HCl 500 mg Injection Single-Dose Vial Neoral® Cyclosporine, Modified 25 mg Capsule Blister Pack 30 Capsules Cyclosporine 100 mg / mL Solution Bottle 50 mL Benlysta® Belimumab 400 mg Injection Single-Use Vial 20 mL
Manufacturer # 4940101010100004029809000780246150007472695049401010201
Brand Benlysta®Cellcept®Neoral® Benlysta®
Manufacturer Glaxo Specialty (Medical Benefit)RocheNovartisAbbVie IncGlaxo Specialty (Medical Benefit)
Invoice BENLYSTA, VL 120MG/5MLCELLCEPT, VL 500MG 20ML (4/CT)NEORAL 25MG SGC 30/BX UD 393298 SOFTGEL CAPSUGENGRAF, SOL ORAL 100MG/ML 50MLBENLYSTA, VL 400MG/20ML
    Log In to Order   Log In to Order   Log In to Order   Log In to Order   Log In to Order

Comparison
Alternate Manufacturer Number 12132142441111
Container Type Single-Use VialSingle-Dose VialBlister PackBottleSingle-Use Vial
Country of Origin UnknownItalyUnknownUnited StatesUnknown
Dosage Form InjectionInjectionCapsuleSolutionInjection
Generic Drug Code 4756913918
Generic Drug Name BelimumabMycophenolate Mofetil HClCyclosporine, ModifiedCyclosporineBelimumab
NDC Number 4940101010100004029809000780246150007472695049401010201
Product Dating McKesson Acceptable Dating: we will ship >= 180 daysMcKesson Acceptable Dating: we will ship >= 90 daysMcKesson Acceptable Dating: we will ship >= 90 daysMcKesson Acceptable Dating: we will ship >= 90 daysMcKesson Acceptable Dating: we will ship >= 180 days
Quantity 30 Capsules
Storage Requirements Requires RefrigerationRequires Refrigeration
Strength 120 mg500 mg25 mg100 mg / mL400 mg
Type IntravenousIntravenousUnit DoseOralIntravenous
UNSPSC Code 5120240351203203512031015120310151202403
Volume 5 mL50 mL20 mL
Application Immunosuppressive AgentImmunosuppressive AgentImmunosuppressive AgentImmunosuppressive AgentImmunosuppressive Agent
Features and Benefits
  • BENLYSTA is a B-lymphocyte stimulator (BLyS)-specific inhibitor indicated for the treatment of: patients aged 5 years and older with active, autoantibody-positive systemic lupus erythematosus (SLE) who are receiving standard therapy
  • BENLYSTA is a B-lymphocyte stimulator (BLyS)-specific inhibitor indicated for the treatment of: adult patients with active lupus nephritis who are receiving standard therapy.
  • BENLYSTA (belimumab) for injection is a sterile, preservative-free, lyophilized powder for reconstitution and dilution prior to intravenous infusion provided in single‑dose glass vials with a rubber stopper (not made with natural rubber latex) and a flip‑off seal. Each 5‑mL vial contains 120 mg of belimumab.
  • Requires Refrigeration
  • 500 mg mycophenolate mofetil in a 20 mL sterile single-dose vial cartons of 4 vials
  • BENLYSTA is a B-lymphocyte stimulator (BLyS)-specific inhibitor indicated for the treatment of: patients aged 5 years and older with active, autoantibody-positive systemic lupus erythematosus (SLE) who are receiving standard therapy
  • BENLYSTA is a B-lymphocyte stimulator (BLyS)-specific inhibitor indicated for the treatment of: adult patients with active lupus nephritis who are receiving standard therapy.
  • BENLYSTA (belimumab) for injection is a sterile, preservative-free, lyophilized powder for reconstitution and dilution prior to intravenous infusion provided in single‑dose glass vials with a rubber stopper (not made with natural rubber latex) and a flip‑off seal. Each 20‑mL vial contains 400 mg of belimumab.
  • Requires Refrigeration